Epcoritamab,rituximab,cyclophosphamide,doxorubicin,vincristine,prednisone,lenalidomide,bendamustine,cytarabine,dexamethasone,oxaliplatin,carboplatin,gemcitabine,ifosfamide
genmab,abbvie
['epcore,nhl,2', 'epcore,nhl,1', 'leusm', 'rituximab', 'epcore,fl,1', 'epcore,nhl,i,(-ii)', 'lymsm', 'epcoritamab', 'nhl', 'ritux', 'lenalidomide']
congress|#17icml david belada, fakultn nemocnice hradec kr lov discusses the epcore nhl-2 trial evaluating epcoritamab with rituximab+lenalidomide in patients with r/r fl. this combination therapy showed potent antitumor activity and manageable safety profile #lymsm #leusm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm